Gonorrhea is one of the most common bacterial sexually transmitted infections in England. Over 41,000 cases were recorded in 2015, more than half of which occurred in men who have sex with men (MSM).
Introduction
Gonorrhea, caused by the bacterial pathogen Neisseria gonorrhoeae, is one of the most common 2 sexually transmitted infections in England. Incidence has increased year on year since 2008, culminating 3 in over 41,000 cases in 2015 [1] . Around 22,000 of these cases were found in men who have sex 4 with men (MSM), constituting a 20% annual increase. The greatest cause for concern, however, is 5 the rapid growth in antimicrobial resistance. The bacterium has quickly developed resistance to each 6 first-line antibiotic in turn, from penicillin through to cephalosporins, such as cefixime and ceftriaxone [2] . 7 Treatment with ceftriaxone is the last remaining single-drug option in most settings worldwide; however 8 susceptibility is diminishing rapidly [3] . As a result, England and many other countries now recommend 9 treatment of gonorrhea with a dual therapy of ceftriaxone and azithromycin [4] . Ceftriaxone resistance 10 has been detected only sporadically in England; however azithromycin resistance is easily selected for 11 and was prevalent in a recent outbreak [5] . Resistance to azithromycin effectively reduces the current 12 treatment to a monotherapy, making resistance trends increasingly important to monitor against the 13 threat of potentially untreatable gonorrhea. 14 
Public
Heath England (PHE) runs the Gonococcal Resistance to Antimicrobials Surveillance Programme 15 (GRASP) [68] , which has produced a report annually since 2000 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . GRASP monitors trends in 16 resistance and susceptibility to a panel of antibiotics used to treat gonorrhea in England and Wales, and 17 thus informs national treatment guidelines and strategy. In 2004, GRASP began testing for cefixime 18 resistance, defined as having a Minimum Inhibitory Concentration (MIC) of 0.125 mg/l [10] . In 2005, 19 following worrying increases in resistance to the previous therapy, ciprofloxacin, a new recommendation 20 was introduced that uncomplicated gonorrhea should be treated with a single dose of cefixime [22] . 21 Fig 1 shows the trends in cefixime prescription and resistance in England. Very little resistance was 22 detected until 2007, however by 2009 the total level of resistance had passed the 5% threshold at which 23 the WHO recommends that first-line treatment guidelines should be changed [13, 23] . At this time almost 24 60% of gonorrhea diagnoses were being treated with cefixime [15] . The majority of the resistance was 25 concentrated in the MSM population, where it reached a peak of 33% in 2010 [16] . This evidence, 26 combined with increasingly common reports of cefixime treatment failure, formed the basis for the 27 decision in May 2011 for another update to the treatment guidelines for uncomplicated gonorrhea [24, 25] . 28 Cefixime was no longer recommended as a first-line treatment, and was replaced with a combination of 29 500mg ceftriaxone and 1g azithromycin [4] . Since 2011, cefixime prescribing has fallen drastically, in 30 line with the updated guidelines. Over the same period the proportion of cefixime-resistant isolates has 31 declined steadily in MSM, falling to less than 1% in 2014 [20] . 32 We hypothesize that the resistance trend observed can be explained by a net fitness benefit to cefixime 33 resistance when cefixime is widely prescribed but a net fitness cost when cefixime prescriptions decline. 34 Understanding the relationship between antibiotic use and the emergence of resistance in gonorrhea has 35 been identified as a key research agenda [26] . Here our main aim is to further the understanding of the 36 evolutionary dynamics of cefixime resistance, and to use this newfound knowledge to inform public health 37 practice. There is still much we do not understand about the natural history of gonorrhea, especially 38 since unobserved asymptomatic infections have long been thought to be an important reservoir of 39 infection. The proportion of incident cases that are asymptomatic at each bodily site of infection is 40 known to vary, but has not been definitively measured [27] [28] [29] . Furthermore, the expected duration of 41 carriage of asymptomatic gonococcal infection is not well studied. Estimates have been traditionally in 42 the region of six months, however recent work using genomic data on pairs of known sexual contacts 43 has suggested that a longer duration of carriage can occasionally happen [30] . We therefore developed 44 and applied a Bayesian statistical approach to account for these uncertainties in the epidemiology of 45 gonorrhea. 46 47 Epidemiological Data 48 The total number of diagnoses of gonorrhea in MSM in England between 2008 and 2015 were extracted 49 from the Genitourinary Medicine Clinic Activity Dataset (GUMCAD) [60] . This mandatory reporting 50 system provides data on diagnoses of sexually transmitted infections from sexual health services in 51 England, and the GUMCAD data is published annually by PHE on their website at http://www.gov. 52 uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables. This 53 yearly number of gonorrhea diagnoses is denoted Y (t). 54 The number of cases of gonorrhea in MSM that were cefixime-resistant and reported by GRASP 55 between 2008 and 2015 were extracted from the corresponding GRASP reports [14] [15] [16] [17] [18] [19] [20] [21] and denoted 56 Y res (t). The coverage of GRASP was calculated for every year between 2008 and 2015 by taking the 57 ratio between the number of cases included in GRASP (irrespective of resistance) and the number 58 of GUMCAD diagnoses in the same year. This GRASP coverage proportion is denoted q(t). The 59
proportion of gonorrhea cases that were treated with cefixime, as opposed to other antibiotics, was also 60 extracted from the GRASP reports between 2008 and 2015. This time-dependent proportion is denoted 61 ⇡(t) and illustrated in The MSM population is estimated at N = 1.5 million, based on a sexually active male population of 63 20 million [33] . In the third National Survey of Sexual Attitudes and Lifestyles (Natsal) 8.4% of men 64 reported same-sex experience at least once, with 2.6% of men having had a same-sex partner in last 65 five years, putting a plausible range for the MSM population at 0.5 and 1.7 million [34] . Natsal is known 66 to under-represent MSM so an estimate towards the top of the range was adopted [35] . Given the 67 low prevalence of gonococcal infection in the population, the total population size is not expected to 68 excessively affect the results. 69 In order to investigate the fitness cost and benefit of cefixime resistance in gonorrhea, we created a 71 stochastic compartmental model, illustrated in Fig 2 with notation summarised in Table 1 . High rates 72 of reinfection with gonorrhea have been observed, suggesting low levels of acquired immunity [31] , 73 and experimental urethral infection in male volunteers found no protection was conferred on repeat 74 infection with an identical strain six months apart [32] . It was therefore assumed that no immunity was 75 with cefixime (T res;cef ) for whom treatment failure happens and who become asymptomatically infected 92 (A res ) [51, 69] . 93 The basic reproduction number, R 0 , is a measure of the reproductive capacity of an infectious agent 95 and is defined as the average number of secondary cases of gonorrhea arising from the introduction of 96 a typical infected individual in a completely susceptible population. Where there is direct competition 97 between strains, as in the situation we are modelling, the strain with the highest R 0 will outcompete the 98 others. 99 To calculate R 0 we must consider the generation-time, defined as the expected time from an individual 100 becoming infected to infecting another individual [37] . By considering the expected time spent in each 101 compartment of the model corresponding to infection with the susceptible strain (ie. states U sus , E sus 102 and A sus in Fig 2) , we derive an analytical expression of the basic reproduction number R sus 0 for the 103 susceptible strains:
Similarly, the basic reproduction number R res 0 for the resistant strains is given by:
Bayesian inference 106 We considered the data as a Partially Observed Markov Process, with the number of GUMCAD recorded cases, Y (t), and GRASP reported resistant cases, Y res (t), being the observed realisations of the underlying unobserved processes: the total incidence of gonorrhea infections, Z(t), and incidence of cefixime-resistant infections, Z res (t). The reporting process for the total number of cases recorded by GUMCAD was set to allow for a 10% under-reporting rate on average, with a 10% margin of error:
The probability of a cefixime-resistant case of gonorrhea being sampled by the GRASP study was assumed to be Poisson distributed with a sampling probability denoted q(t) derived from the coverage of the GRASP study over 2008 to 2014:
Based on these observations we aimed to infer the values of the ten parameters: A sus (0), A res (0), ✓, , , ⌫, 107 ↵, µ, ⇢ and . 108 An analytical expression for the likelihood of the observed data given our model is not available, so 109 we obtained an unbiased estimate of the likelihood using a particle filter [38] . The estimated likelihood 110 was then incorporated into a particle Monte Carlo Markov Chain (pMCMC) which was used to obtain a 111 sample from the posterior distribution of the model parameters [39] . 112 The model fitting was implemented using the R package pomp, which includes a pMCMC algorithm 113 that can be used to perform Bayesian inference [40] . The algorithm was modified to enable parallel 114 computation. The particle filter estimation of the likelihood was based on 1,000 particles, which was 115 sufficiently robust to estimate the likelihood. 6 million iterations of the pMCMC were thinned by a 116 factor of 100. Four separate chains were run with dispersed starting points, and compared using the R 117 package coda [41] . The chains were found to have converged to the same posterior distribution based 118 on the multivariate version of the Gelman-Rubin diagnostic, which was less than 1.1 for all inferred 119 parameters [42, 43] . To ensure maximum robustness, the samples from the four chains were then 120 combined, and found to have an effective sample size of more than 150 for all parameters.
121
Prior distributions of parameters 122 Bayesian inference requires setting plausible priors for the model parameters. We used highly un-123 informative Uniform(0,1) priors for the two proportion parameters and and Uniform(0, 1) priors 124 for the three parameters A sus (0), A res (0) and ↵, which is an improper distribution but does not lead 125 to an improper posterior distribution. For the five remaining parameters ✓, ⌫, , µ and ⇢ we assigned 126 informative Gamma priors based on literature review, as summarised in Table 1 . 127 The transmission rate of infection, represented by the parameter ✓, encompasses both the average 128 number of sexual partners per year and the transmission probability per partnership. The Natsal-3 129 survey observed a mean number of sexual partners per year for MSM of 4.4 [34] and we would therefore 130 expect ✓ to be slightly lower, to reflect the fact that not all contacts result in transmission. The prior 131 distribution for ✓ was therefore set such that it was between 2.9 and 6.3 with 99% prior weight. 132 The expected duration of carriage for asymptomatic gonorrhea is not well measured. A study of 18 133 asymptomatic infected men saw no resolution in urethral infection in the 165 days until they received 134 treatment [51] . Estimates of the duration of carriage in modelling studies have been based on calculations 135 that take into account observed prevalence and assumed proportion of unobserved infection, and are 136 often in the region of 6 months [52] [53] [54] . However, in recent work using genomic data, the greatest 137 observed time to most recent common ancestor for bacterial genomes from known contact pairs was 8 138 months, suggesting that this estimate needs to be increased [30] . Duration of carriage may depend on 139 infection site, for pharyngeal gonorrhea it has been estimated at 12 weeks, and for rectal infection has 140 been estimated at one year [49, 55] . The parameter ⌫ was therefore assigned a prior that corresponded 141 to a mean duration of carriage between three months and one year with 99% prior weight. 142 The duration of the incubation, symptomatic and treatment stages of infection have been estimated to 143 be short, in the region of days rather than weeks [45] [46] [47] . Gamma priors were accordingly assigned to 144 each of the three parameters , µ and ⇢.
145
Estimation of model parameters 147 We fitted our model of gonorrhea transmission to two different time series over the years 2008 to 2014: 148 the total number of gonorrhea diagnoses in MSM in England [44] and the incidence of cefixime-resistant 149 gonorrhea [14] [15] [16] [17] [18] [19] [20] . The posterior distribution of parameters shown in Fig 3 was obtained through 150 Bayesian inference, implemented using a pMCMC method [39] . For each parameter we report the 151 posterior mean estimate and 95% credibility interval shown in brackets ( The posterior distribution of the rate of transmission, ✓, suggests a higher mean rate of infection than 156 the prior expectation: 5.2 (4.2, 6.5), but the prior and posterior credible intervals overlap to a large 157 extent, suggesting that the results are consistent with our prior knowledge. Our model predicts that the 158 proportion of infections that become symptomatic is 62% (46%, 77%). The three parameters , µ and 159 ⇢, corresponding respectively to the durations of the incubation period, symptomatic infection before 160 seeking treatment, and the treatment phase, had posterior distributions similar to their prior distributions, 161
indicating that the prior distributions were appropriate but that there is little additional information on 162 these parameters in the data set. The posterior distribution of ⌫ has a slightly lower mean than prior, 163 implying a longer mean duration of carriage of 193 days (118, 397). The prior and posterior credible 164 intervals still intersect to a large extent so there is not significant evidence of a departure from the prior 165 based on the data. 166 9
The last two parameters, ↵ and , capture the difference between the susceptible and resistant strains 167 in our model. The model predicts that in order to replicate observed incidence patterns recovery from 168 asymptomatic cefixime-resistant gonorrhea occurs ↵ =1.7 (1.4, 2.4) times faster than asymptomatic 169 cefixime-susceptible gonorrhea, giving rise to a fitness cost. The model suggests a treatment failure 170 proportion of =84% (55%, 100%) for resistant gonorrhea treated with cefixime, so that resistance 171 confers a fitness benefit in an environment in which cefixime is highly prescribed. the real data. The real data are within the 95% predictive intervals at all time points, indicating a good fit 187 of the model to the data [57] . 188 The total number of cases of gonorrhea observed by GUMCAD, and the number of cefixime-resistant 189 cases observed by GRASP in 2015 [21] were not used in the model fitting process, and were used to 190 provide an independent check of the model fit. Both data points are within the 95% probability intervals 191 predicted by our model: 21,915 gonorrhea diagnoses were recorded by GUMCAD, compared to 27,668 192 (18, 144, 41, 054) diagnoses predicted by the model; 10 cefixime-resistant cases were recorded by 193 GRASP, compared to 4 (0, 14) cases predicted by the model. Our modelling suggests that in 2015 0.7% 194 (0.4%, 1.1%) of MSM in England may be carriers of asymptomatic gonorrhea. 196 A key threshold in epidemic theory associates the persistence of disease in a population with a 197 basic reproduction number greater than one [58] . Using Eq 1 we obtain a posterior estimate for 198 the basic reproduction number for cefixime-susceptible infection of R sus 0 = 1.18 (1.09, 1.35) , which 199 suggests that the cefixime-susceptible strain of gonorrhea is expected to persist in the population without 200 further intervention ( Fig 5A) . Under our hypothesis the basic reproduction number for cefixime-resistant 201 gonorrhea depends on the frequency of cefixime prescription (Eq 2) and so can be considered as a 202 function R res 0 (⇡) where ⇡ is the proportion of gonorrhea diagnoses being treated by cefixime. In the 203 two extreme cases when no cefixime is prescribed (⇡ = 0, meaning that treatment is always effective) 204 and only cefixime is prescribed (⇡ = 1, meaning that only a proportion 1 of treatment is effective) 205 we estimate a basic reproduction number for resistant gonorrhea of R res 0 (0) = 0.73 (0.62, 0.83) and 206 R res 0 (1) = 1.60 (1.38, 1.90), respectively. At its height in 2008 the frequency of cefixime prescriptions was 207 70%, we estimate that at this time the basic reproduction number for resistant gonorrhea was R res 0 (0.7) = 208 1.34 (1.22, 1.51) . The former estimate is ¡ 1 whereas the latter two are ¿ 1, which is consistent with 209 the fact that between 2005 and 2010, when cefixime was often used to treat gonorrhea, resistance 210 to cefixime increased whereas with the discontinuation of cefixime usage from 2011 resistance has 211 decreased. 212 We can estimate the frequency of cefixime prescriptions above which we expect the resistant strain 213 to persist, corresponding to when the fitness benefit of cefixime resistance is greater that its fitness 214 cost, by setting R res 0 (⇡) = 1 and solving for ⇡ in Eq 2. We denote this threshold ⇡ {R res 0 =1} , and thus 215 obtain a posterior estimate of ⇡ {R res 0 =1} = 0.31 (0.26, 0.36) ( Fig 5B) . This result suggests that up to a 216 quarter of gonorrhea treatments could be with cefixime monotherapy without causing a cefixime-resistant 217 epidemic. Another important threshold is the level of cefixime prescriptions above which the resistant 218 strain of gonorrhea is fitter than the susceptible strain. We denote this threshold ⇡ Fig 6A shows that, when more than 35% of gonorrhea cases were treated with 230 cefixime, there was a 95% probability that the resistant outbreak persisted in 2015. This is comparable 231 to our estimate of ⇡ {R res 0 =1} = 0.31 (0.26, 0.36) ( Fig 5B) , the level of prescriptions above which the fitness 232 benefit of cefixime resistance is greater than the fitness cost.
195

Comparative analysis of basic reproduction numbers
233 Fig 6B shows that, when more than 50% of gonorrhea cases were treated with cefixime, the simulated 234 incidence of cefixime-susceptible infection began to fall, with the cefixime-resistant strain becoming 235 more common. This supports our analytical estimate of ⇡ {R sus 0 =R res 0 } = 0.51 (0.43, 0.62) (Fig 5C) , the 236 level of cefixime prescriptions above which the resistant strain becomes fitter than the susceptible strain. 237
If cefixime were used to treat more than 60% of cases then the level of cefixime resistance would 238 become greater than 50% at the end of the eight year simulation period and if cefixime were used to 239 treat all cases resistance would be close to 100%.
240
Discussion 241 We have used mathematical modelling and Bayesian inference methods to uncover insights into the 242 dynamics of cefixime resistance in gonorrhea. We quantified both the fitness cost and fitness benefit of 243 resistant strains, which allowed us to make predictions about the future prevalence of resistance as a 244 function of how often cefixime is prescribed. Our results indicate that cefixime could be used to treat 245 uncomplicated cases of gonorrhea without incurring the risk of causing a resistant epidemic like the 246 one that happened in 2007-2012, provided its frequency of use were controlled, enabling continued use 247 of an 'abandoned' antibiotic. Our analysis suggests that cefixime could be used to treat up to 25% of 248
cases, but this threshold should be used cautiously for reasons described below. 249 Our modelling approach requires making a number of assumptions, and it is important to consider their 250 suitability. For example, it was assumed that all cefixime-susceptible infections were cured, regardless 251 of which antibiotic was prescribed. The prescription data shows that between 2008 and 2015 the 252 vast majority of non-cefixime prescriptions were for ceftriaxone, either alone or in combination with 253 azithromycin, so the assumption of cure is reasonable given that ceftriaxone resistance reports remain 254 sporadic in England. Our model implicitly assumes that there is no co-infection with both strains, 255 and no evolution of resistance happening within-host. This simplification has been used in a number 256 other studies on the epidemiology of antimicrobial resistance [61, 62] . Ignoring within-host competition 257 between resistant and susceptible strains following co-infection is justified here by the fact that both 258 strains have low prevalence, making co-infection very unlikely. Within-host evolution of resistance was 259 included in a recent gonorrhea modelling study [67] but clearly this is a rare event which only increases 260 by one the number of resistant infections, which we estimated to be already equal to 49 at the start of 261 the epidemic simulation on the 1st January 2008. 262 Our model also makes assumptions concerning the cost and benefit of cefixime resistance. The fitness 263 cost of the mutation conferring resistance is assumed to be constant over time, however compensatory 264 mutations have been observed in other bacterial pathogens that reduce the initially high fitness cost 265 of antibiotic resistance [59, 63] . It is clear from our analysis that there was a substantial fitness cost 266 to cefixime resistance when the prescription protocol was changed in 2010, which is the reason why 267 the resistance level subsequently fell. We cannot rule out that compensatory mutations took place 268 after resistance initially emerged, but this would mean that the initial cost was even higher and in these 269 conditions resistance would have been unlikely to emerge at all. Our formulation of the dynamics of the 270 fitness cost of resistance was via a reduction in the duration of asymptomatic carriage. In the absence 271 of evidence of the resistance mechanism the fitness cost could plausibly be modelled through reduced 272 transmissibility of the resistant strain [67] , which would not affect our overall conclusions, in particular 273 regarding the basic reproduction number analysis and predictions of the impact of cefixime usage on 274 future resistance trends. 275 The ceftriaxone-azithromycin dual therapy is currently effective, but it represents a last resort, so that we 276 urgently need a strategy for what would be done if it stopped working. It is likely to be just a matter of 277 time before this happens, with the first reported failure of the dual therapy having occurred in 2015 [65] . 278 Resistance to azithromycin was detected in a recent outbreak that started in the North of England [5] , 279 and is now reported in almost 10% of tested isolates [21] . Resistance to ceftriaxone remains rare, but 280 minimum inhibitory concentration (MIC) levels have been steadily increasing [66] . If alternative treatment 281 options could be used, even for a minority of cases, then it would delay and maybe even prevent the 282 emergence of resistance to the dual-therapy antibiotics by reducing the fitness benefit it would confer. 283 For some previously used antibiotics, such as penicillin or ciprofloxacin, significant levels of resistance 284 remain in the gonococcal population (24% and 39% in 2015, respectively [21] ), so that they could 285 not be recommended even for a small fraction of cases. These antibiotics could be prescribed only if 286 drug-sensitivity could be quickly established, for example using real-time PCR assays [70, 71] , or whole 287 genome sequencing [64, 72] , which both remain experimental. In contrast, the fact that resistance to 288 cefixime has become very low in England (around 1% in 2015, [21] ) makes it a prime candidate for return 289 into action without the need for case-by-case susceptibility testing. Perhaps the greatest threat posed by 290 this proposed strategy would be the evolution of compensatory mutations which could reduce the fitness 291 cost of resistance. As previously mentioned, compensatory mutations do not seem to have emerged 292 during the 2007-2012 cefixime-resistant epidemic, but if they did the acceptable prescribing proportion 293 would be lowered, and the probability of persistence of cefixime resistance increased. Therefore, a 294 redeployment of cefixime would require close monitoring of resistance trends in England [68] and 295 beyond [73, 74] . S1 Appendix. Model equations and stochastic simulations. We developed a simple susceptible-299 infected-susceptible (SIS)-type stochastic compartmental model that describes the transmission and 300 natural history of gonorrhea, as illustrated in Fig 1 with parameters summarised 
We used a stochastic version of the model described in Eqs S1-S6. The process was initialised on 31 December 2007, with an initial number of asymptomatic infections A s (0) for s 2 {sus, res}, and the remainder of the population being susceptible. Simulation proceeds through repeated iterations of the steps below for each day. Transition variables d 1 , ..., d 17 are drawn from the following distributions:
, ⇡(t)µ, (1 ⇡(t))µ (S10) d 9 , d 10 ⇠ Multinom E res (t), ⇡(t)µ, (1 ⇡(t))µ (S11) 
The compartments of the model are then updated as follows:
S(t + 1) := S(t) d 
